NDAINHALATIONGAS
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
NITROGEN, NF (nitrogen) by Advanced Solutions Life Sciences. Approved for nutrition therapy, postoperative complications, superficial basal cell carcinoma and 1 more indications. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NITROGEN, NF is an inhalation gas approved by the FDA for nutrition therapy, postoperative complication management, superficial basal cell carcinoma treatment, and gastrointestinal neoplasm applications. As a non-pharmacologic gas product, it operates outside traditional small-molecule and biologic frameworks, with mechanism of action determined by clinical context rather than receptor binding.
Peak
Product is in peak stage with established market presence but limited available commercial spend data suggests niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on NITROGEN, NF at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.